Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma

被引：0

作者：

Elias, Alexandra ^{[1
]}

Marques-Piubelli, Mario L. ^{[2
]}

Nair, Ranjit ^{[3
]}

Prakash, Rishab ^{[4
]}

Ahmed, Sairah ^{[4
]}

Malpica, Luis

Lee, Hun Ju ^{[4
]}

Xu, Jie ^{[6
]}

Flowers, Christopher R. ^{[4
]}

Neelapu, Sattva S. ^{[4
,6
]}

Vega, Francisco

Miranda, Roberto ^{[6
]}

Iyer, Swami P. ^{[5
]}

机构：

[1] McGovern Med Sch, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Pearland, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[5] Univ Texas MD Anderson Canc Ctr, Lymphoma & Myeloma, Houston, TX USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187939

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[41] Frequency, Histologic, and Prognostic Significance of CD30 Expression in AIDSassociated Diffuse Large B-Cell Lymphoma
Chaudhry, Amina
Tariq, Muhammad Junaid
Shah, Eshana
De Marco, Camille E.
Reid, Erin G.
Cesarman, Ethel
Chadbum, Amy
Rubinsten, Paul
BLOOD, 2021, 138
[42] Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+lymphoid neoplasms treated with brentuximab vedotin
Goyal, Amrita
Patel, Sanjay
Goyall, Kavita
Morgan, Elizabeth A.
Foreman, Ruth K.
JOURNAL OF CUTANEOUS PATHOLOGY, 2019, 46 (11) : 823 - 829
[43] Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+lymphoid neoplasms treated with brentuximab vedotin
Goyal, K.
Goyal, A.
Patel, S.
Morgan, E. A.
Foreman, R. K.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : B13 - B13
[44] Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma
Gentille, Cesar
Sarfraz, Humaira
Joshi, Jitesh
Randhawa, Jasleen
Shah, Shilpan
Pingali, Sai Ravi
CANCER REPORTS, 2022, 5 (07)
[45] Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+T cell lymphoma
Oberic, Lucie
Delzor, Faustine
Protin, Caroline
Perriat, Sophie
Laurent, Camille
Grand, Anais
Canonge, Jean Marie
Borel, Cecile
Gauthier, Martin
Ysebaert, Loic
Puisset, Florent
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (07) : 1730 - 1735
[46] Targeting BCL-xL overcomes resistance to brentuximab vedotin in CD30+T-cell lymphoma
Schmidt, C., V
Ackermann, P. N. F.
Ries, L.
Schmidt, N.
Ksionsko, N.
Shumilov, E.
Wulf, G. G.
Koch, R.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 191 - 191
[47] Sensitivity to brentuximab vedotin depends on CD30-expression levels in different subtypes of cutaneous T-cell lymphoma cell lines
Hofer, Vivian
Wobser, Marion
Maurus, Katja
Houben, Roland
Schrama, David
Goebeler, Matthias
Rosenwald, Andreas
EUROPEAN JOURNAL OF CANCER, 2023, 190 : S25 - S26
[48] Vorinostat Downregulates CD30 and Decreases Brentuximab Vedotin Efficacy in Human Lymphocytes
Hasanali, Zainul S.
Epner, Elliot M.
Feith, David J.
Loughran, Thomas P., Jr.
Sample, Clare E.
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) : 2784 - 2792
[49] Frontline Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin and Prednisone in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression (SGN35-032, Trial in Progress)
Jagadeesh, Deepa
Knowles, Scott
Horwitz, Steven M.
BLOOD, 2021, 138
[50] Sensitivity to brentuximab vedotin depends on CD30-expression levels in different subtypes of cutaneous T-cell lymphoma cell lines
Hofer, V.
Wobser, M.
Maurus, K.
Houben, R.
Schrama, D.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 92 - 92

← 1 2 3 4 5 →